Entera Bio Ltd. Income Statement
ENTX|5 years of annual SEC 10-K data (FY2021-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 5 fiscal years. All figures from audited SEC 10-K filings.
At a glance
Revenue
$181,000
FY2025
Gross Profit
$9,000
5.0% gross margin
Operating Income
-$10M
FY2025
Net Income
-$10M
FY2025
Entera Bio Ltd. reported $181,000 in revenue and $10M in net loss for FY2025. Revenue has declined at a 16.1% compound annual rate over the past 4 years.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score NaN (distress zone, below 1.23 threshold)
- Piotroski F-Score: 2/9 criteria passed
- Currently unprofitable: Net income is negative
- Cash-backed earnings: Operating cash flow exceeds net income
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $181.0K | $0 | $134.0K | $571.0K | $365.0K |
| Cost of Revenue | $172.0K | $0 | $101.0K | $373.0K | $300.0K |
| Gross Profit | $9.0K | $0 | $33.0K | $198.0K | $65.0K |
| SG&A Expense | $340.0K | $4.4M | $7.3M | $5.7M | $4.9M |
| R&D Expense | $4.5M | $4.5M | $5.8M | $6.8M | $6.4M |
| Operating Income | -$9.6M | -$8.9M | -$13.0M | -$12.2M | -$11.2M |
| Income Tax | $14.0K | $29.0K | $137.0K | -$59.0K | $20.0K |
| Net Income | -$9.5M | -$8.9M | -$13.1M | -$12.2M | -$11.2M |
| EPS (Basic) | $0.25 | $0.31 | $0.45 | $0.47 | - |
| EPS (Diluted) | $0.25 | $0.31 | $0.45 | $0.47 | $0.67 |
| Shares Outstanding | 38.8M | 35.5M | 28.8M | 28.8M | 21.1M |
| Gross Margin | 5.0% | - | 24.6% | 34.7% | 17.8% |
| Operating Margin | -5295.6% | - | -9714.2% | -2139.6% | -3059.7% |
| Profit Margin | -5271.3% | - | -9754.5% | -2134.3% | -3072.9% |